Diabeter
Diabeter is a Netherlands-based specialized treatment center exclusively focused on Type 1 diabetes and MODY, serving 5,000+ patients across five centers via its CE-marked CloudCare remote monitoring platform and AID/Hybrid Closed Loop systems. The Medtronic subsidiary delivers value-based reimbursed diabetes care.
- Company typePrivate
- Founded2001
- HeadquartersRotterdam, Netherlands
- Headcount11–50
- GTM typeB2C
- OfferingServices
What Diabeter does
Diabeter Nederland B.V. is a Netherlands-based specialized treatment center focused exclusively on Type 1 diabetes and maturity-onset diabetes of the young (MODY), operating five centers across Rotterdam (headquarters), Deventer, Groningen, Eindhoven, and Amsterdam (Diabeter Centrum Amsterdam, a joint venture with Amsterdam UMC opened November 2023). The organization serves more than 5,000 individuals through a hybrid care model that combines in-person consultations with the proprietary CloudCare platform, a CE-marked remote monitoring system that ingests continuous glucose monitoring data from multiple device ecosystems (CareLink, LibreView, Glooko) and applies algorithms to detect deviations, alert clinicians, and prioritize patients needing intervention. CloudCare integrates with Automated Insulin Delivery (AID) / Hybrid Closed Loop systems, and complementary products include the Diabeter patient app and Mediforen visual consultation tools used by diabetes nurses and dietitians.
Diabeter is a subsidiary of Medtronic following the April 2015 acquisition, which was intended to scale the Dutch value-based care model internationally while preserving clinical independence. The business model is healthcare-services reimbursement under the Dutch basic health insurance package (zorgverzekering / basiszorg); Diabeter holds contracts with all Dutch health insurers and a long-term agreement with Zilveren Kruis, with device and consumable distribution handled through Diabstore (diabstore.nl). Patient outcomes cited by the organization include 22% of all patients achieving normal HbA1c (60% among AID users), 75% reaching important diabetes targets, only 3% hospitalized due to diabetes-related issues, and 95% reporting improved quality of life. Revenue is not publicly disclosed and the entity operates as a private limited company.
The company pursues a research-oriented extension of its clinical model, partnering with Amsterdam UMC, UMCG, and LUMC on studies such as the Dsense immune retraining project and the BREBAD trial (Breakthrough T1D-funded, 2026) investigating 6-bromotryptophan supplementation to slow or prevent Type 1 diabetes. Additional alliances include RondOm Loven Groep for podiatry, lifestyle intervention, and psychological support (via OnsPsychologie), and a CloudCare deployment at UZ Brussels marking the first international (Belgian) rollout. Certifications include Qualicor Europe Gold (since August 2022) and HKZ client/patient safety certification (since 2013, audited annually by Lloyds).
Diabeter firmographics
Firmographics- Name
- Diabeter
- Legal name
- Diabeter Nederland B.V.
- Website
- https://diabeter.nl
- Company type
- Private
- Founded year
- 2001
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Diabeter is a Netherlands-based specialized treatment center exclusively focused on Type 1 diabetes and MODY, serving 5,000+ patients across five centers via its CE-marked CloudCare remote monitoring platform and AID/Hybrid Closed Loop systems. The Medtronic subsidiary delivers value-based reimbursed diabetes care.
- Ownership category
- akta.pro rank
Diabeter industry classification
Industry- Product category
- Type 1 Diabetes Care Services
- NAICS
- Health Care and Social Assistance (62)
- SIC
- Services-Offices & Clinics Of Doctors Of Medicine (8011)
- akta.pro primary industry
- Type 1 Diabetes Care (HLAKADAB)
- akta.pro secondary industries
- Endocrinology & Diabetes Telemedicine Platforms (HLALAGAD), Automated Insulin Delivery (AID) / Closed-Loop Systems (HLAHAHAF)
Keywords
Where Diabeter is headquartered
LocationHeadquarters
- HQ city
- Rotterdam
- HQ country
- Netherlands
- HQ region
- Europe
Offices5 records
Markets served
Diabeter business model
Business model- GTM type
- B2C
- Offering type
- Services
- Cost components
- Personnel
Revenue model
- Healthcare Services Reimbursement: Diabeter provides specialized type 1 diabetes treatment services reimbursed through the Dutch health insurance system (zorgverzekering). Diabetes care falls under basic healthcare coverage in the Netherlands. The organization has contracts with all health insurers and long-term agreements with Zilveren Kruis (10 years) and ongoing negotiations with CZ.
- Medical Device Supply (Diabstore): Through Diabstore (diabstore.nl), the organization supplies glucose meters, sensors, insulin pumps and other diabetes supplies. Contracts exist with all health insurers for equipment reimbursement.
- Scientific Research: Conduct clinical research in partnership with academic institutions (Amsterdam UMC, UMCG, LUMC) funded by organizations like Breakthrough T1D, JDRF, and Diabetes Fonds.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Healthcare services covered by Dutch basic insurance |
Go-to-market motion2 records
Distribution channels4 records
Marketing channels6 records
Diabeter product offering
Product offeringCore offering
Diabeter is a specialized healthcare provider delivering treatment and care for patients with type 1 diabetes and MODY diabetes, with 5,000+ patients across five Netherlands treatment centers. It combines in-center consultations with its proprietary CloudCare CE-marked remote monitoring platform, supporting continuous glucose monitoring, automated insulin delivery systems, and 24/7 emergency support. All care is reimbursed under Dutch basic health insurance.
Product overview
Diabeter offers a comprehensive diabetes care ecosystem centered on CloudCare, a CE-marked monitoring platform that connects to patients' glucose sensors, insulin pumps, and meters. The CloudCare system analyzes data through algorithms to identify patients needing support, enabling proactive care delivery. Patients interact through the Diabeter App for personal health data access. Education is supported through Mediforen visual conversation cards used in consultations. Equipment and supplies are available through Diabstore partner organization. All services are delivered through five treatment centers in the Netherlands (Rotterdam, Groningen, Deventer, Eindhoven, and Amsterdam UMC collaboration).
Differentiator
Problem solved
Functional benefit
Brands
- CloudCare: A monitoring system that provides healthcare providers with direct and secure insight into glucose data of people with type 1 diabetes.
- Diabstore
Products and services
- CloudCare
- Diabeter App
- Mediforen
- Diabstore
- Type 1 Diabetes Treatment & Care
- MODY Diabetes Treatment & Care
Quantifiable outcome
- 22% of all patients achieve normal HbA1c (<48 mmol/mol), rising to 60% among AID system users
- +5 more outcomes
Companies that use Diabeter
Customer profileNamed customers4 records
Segments3 records
Ideal customer profiles3 records
Diabeter technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration3 records
AI capability4 records
Feature4 records
Diabeter partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered supporting, core and strategic.
- Diabetesvereniging NederlandsupportingCo-organization of Diabetes TechLab events to educate people about diabetes technology, providing information about different devices and allowing people to share experiences.
- RondOm Lopen GroepcoreComprehensive partnership for type 1 diabetes care focused on four pillars: (1) Podotherapy for foot care and prevention, (2) Combined Lifestyle Intervention (GLI) program, (3) Psychological support through OnsPsychologie, and (4) Scientific research collaboration. The partnership aims to improve quality of life through foot care, exercise, lifestyle interventions, and mental health support.
- UZ BrusselsstrategicImplementation of CloudCare monitoring system in the pediatric hospital of University Hospital Brussels. UZ Brussels is the first center in Belgium to implement CloudCare, enabling continuous monitoring of glucose levels and weekly reports for children with type 1 diabetes.
- Amsterdam UMCcoreJoint venture to operate Diabeter Centrum Amsterdam (DCA), a specialized advanced treatment center for type 1 and hereditary diabetes. The center opened November 2023 and combines personalized care, advanced treatment methods, and leading scientific research aiming for a life without diabetes complications.
- OnsPsychologiesupportingCollaboration for mental health care services integrated into diabetes treatment, helping people with type 1 diabetes access psychological support.
- LUMC (Leiden University Medical Center)strategicCollaboration on Dsense research aiming to 'retrain' the immune system of people with type 1 diabetes using the body's own tolerogenic dendritic cells to stop attacking insulin-producing cells.
- Amsterdam UMC Research TeamstrategicJoint research team including internist Prof. Dr. Max Nieuwdorp and immunologist Dr. Elena Rampanelli conducting the BREBAD clinical study on 6-BT supplement for type 1 diabetes.
Scale indicators8 records
Recent moves7 records
Expansion highlights6 records
Diabeter competitors and assessment
Company assessmentDirect peers
- Glooko: Diabetes data aggregation and population management platform that integrates CGM, pump, and meter data for clinicians — directly competes with Diabeter's CloudCare offering in remote monitoring and analytics.
- Tidepool: Non-profit diabetes data platform supporting multiple device types and population-level analytics; competes with CloudCare on the same clinician-facing data integration and population monitoring use case.
- mySugr (Roche): Patient-facing diabetes management app with clinician data sharing, acquired by Roche; overlaps with Diabeter's Diabeter App and CloudCare hybrid care model.
- Inreda Diabetic: Dutch developer of a fully closed-loop artificial pancreas (Inreda AP); a domestic T1D technology peer that competes for attention in the Dutch AID/HCL market where Diabeter is most active.
Broad incumbents
- Medtronic: Parent company and global incumbent in diabetes (pumps, sensors, AID algorithms) — overlaps with Diabeter through CareLink data integration and the broader Medtronic diabetes franchise.
- Dexcom: Leading CGM manufacturer whose sensors feed CloudCare-integrated platforms; competes indirectly for the same patient monitoring value chain.
- Abbott Diabetes Care: Manufacturer of FreeStyle Libre CGM systems that integrate with CloudCare via LibreView; a major incumbent serving the same T1D patient population.
- Insulet: Omnipod tubeless insulin pump maker competing for AID-system share; its algorithms and hardware are part of the alternative ecosystem Diabeter patients could use.
- Tandem Diabetes Care: t:slim X2 insulin pump with Control-IQ AID algorithm — directly competitive alternative to Medtronic AID systems deployed at Diabeter.
Others
- Breakthrough T1D (formerly JDRF): Global T1D research funding organization and Diabeter's research partner (>USD 1M grant in 2014); comparable as a T1D ecosystem stakeholder with shared research agenda.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks5 records
Key highlights7 records
Customer concentration
Diabeter social profiles
Digital presenceDiabeter compliance and trust
Trust signalCompliance2 records
Diabeter financial estimates
Financial estimateRevenue estimate
Valuation estimate
Diabeter leadership team
Management profileNumber of profiles
Profiles7 records
Diabeter subsidiaries and ownership
Company hierarchySubsidiaries1 record
Diabeter funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Diabeter M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Diabeter
What does Diabeter do?
Diabeter is a specialized healthcare provider delivering treatment and care for patients with type 1 diabetes and MODY diabetes, with 5,000+ patients across five Netherlands treatment centers. It combines in-center consultations with its proprietary CloudCare CE-marked remote monitoring platform, supporting continuous glucose monitoring, automated insulin delivery systems, and 24/7 emergency support. All care is reimbursed under Dutch basic health insurance.
Is Diabeter a public or private company?
Diabeter is a private company. It is classified as corporate owned and is currently operating.
When was Diabeter founded?
Diabeter was founded in 2001. It employs 11 to 50 people.
Where is Diabeter based?
Diabeter is headquartered in Rotterdam, Netherlands, in the Europe region.
How does Diabeter make money?
Three revenue lines are on record. Healthcare Services Reimbursement is the primary driver. The others are medical Device Supply (Diabstore) and scientific Research.
Who are Diabeter's main competitors?
Direct peers on record are Glooko, Tidepool, mySugr (Roche) and Inreda Diabetic. Broad incumbents are Medtronic, Dexcom, Abbott Diabetes Care, Insulet and Tandem Diabetes Care. Breakthrough T1D (formerly JDRF) is listed as an others.
Does Diabeter have an API?
No public API is recorded for Diabeter.
What industry is Diabeter in?
Diabeter's product category is Type 1 Diabetes Care Services. Its primary akta.pro industry code is HLAKADAB, Type 1 Diabetes Care, with a secondary code of HLALAGAD, Endocrinology & Diabetes Telemedicine Platforms. Its NAICS code is 62 and its SIC code is 8011.